ABSTRACT Objective: Our objective was to assess the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812), an oral neuraminidase inhibitor for the treatment of influenza A and B virus in healthy volunteers.
Methods: This was a double-blind, randomized, placebocontrolled, parallel group study. A total of 80 adult male and female subjects were enrolled for the influenza A challenge study. This was a 5-arm study (100 mg/qd, 200 mg/qd, 200 mg/bid, 400 mg/qd, and placebo). In the challenge B virus model, 60 subjects were enrolled for a 3-arm study (800 mg on Day 1 followed by 400 mg on Days 2-5; 800 mg on Days 1-5; and placebo). The pharmacokinetics of RWJ-270201 (BCX-1812) were characterized with the use of a population approach and were described by a 2-compartmental model with firstorder absorption and elimination. The pharmacodynamic data, mean log viral titers, were described with the use of an empirical equation relating the viral growth and the effect of drug on changes in viral titers.
Results: Pharmacokinetic analyses show that weight was the most significant covariate for all estimated pharmacokinetic parameters. The pharmacodynamic data, mean log viral titers showed a decrease in viral titers with increase in plasma exposure. The decrease in viral titer started to occur 12 hours following the drug dosing, and viral suppression lasted 72 hours to 96 hours. The exposures associated with a 50% decrease in viral titers were 1089 ng-h/mL and 1898 ng-h/mL, respectively.
Conclusions: A PK/PD model was well utilized to characterize the effect of RWJ-270201 (BCX-1812) on the influenza A and B virus. The results from this model showed that both the loading dose and the standard dose regimens are efficacious against A and B virus.
RWJ-270201 (BCX-1812) is under clinical development for the treatment of influenza A and B infections in adult and high-risk populations. It is a potent and selective inhibitor of both influenza A and B virus neuraminidases and inhibits the viral cleavage of sialic acid from cell surface glycoproteins and glycolipids. 1, 2 Consequently, RWJ-270201 (BCX-1812) prevents infection by stopping the release of newly formed virus from the surface of infected cells and preventing viral spread across the mucous lining of the respiratory tract. 3 It therefore represents an attractive agent for antiviral therapy.
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METHODS

Design of Challenge Studies
Influenza A Trial: This was a double-blind, randomized, placebo-controlled, parallel group study. A total of 80 adult male and female subjects were enrolled to evaluate the antiviral effect of RWJ-270201 (BCX-1812) in the treatment of experimentally induced influenza challenge strain A virus. Subject numbers were assigned in sequential order at the time of admission to the study isolation unit. Subjects were randomly assigned to 1 of 5 treatment groups: (1) placebo, (2) RWJ-270201 (BCX-1812) 100 mg q24h, (3) RWJ-270201 (BCX-1812) 200 mg q24h, (4) RWJ-270201 (BCX-1812) 200 mg q12h, or (5) RWJ-270201 (BCX-1812) 400 mg q24h. Sixteen subjects were assigned to each treatment group. All doses were administered orally for 5 days. Subjects who withdrew from the study prior to the inoculation with the influenza A were replaced. Influenza B Trial: This was a double-blind, randomized, placebo-controlled, parallel group study. A total of 60 healthy adult subjects were enrolled to evaluate the antiviral effect of RWJ-270201 (BCX-1812) in the treatment of experimentally induced influenza Type B virus. Subjects were randomly assigned to 1 of 3 treatment groups: (1) placebo q24h on Days 1-5, (2) RWJ-270201 (BCX-1812) 800 mg on Day 1 followed by RWJ-270201 (BCX-1812) 400 mg q24h on Days 2-5 [1] [2] [3] [4] [5] . There were 16 subjects per treatment group in the influenza A trial and 20 subjects per treatment group in the influenza B trial. Within each treatment group, subjects were randomly assigned to 1 of the following schedules:
• Group A: All 8 (influenza A trial) or 10 subjects (influenza B trial) had 5 mL blood samples collected at 0 hour (predose) and at 3, 6, 12, and 24 hours after the dose of study drug on Study Day 1; then at 0 hour (predose) on Study Days 2, 3, 4, and 5. In total, there were 80 samples drawn from 8 subjects in influenza A trial and 100 samples drawn from 10 subjects in influenza B trial. In total there were 10 samples per subject.
• Group B: All 8 (influenza A trial) or 10 (influenza B trial) subjects had 5 mL blood samples collected at 0 hour (predose) on Study Days 1, 2, 3, and 4; then at 0 hour (predose) and at 3, 6, 12, and 24 hours after Study Day 5. The total number of samples drawn and the number of samples per subject were similar to Group A.
The blood samples were collected into heparinized Vacutainer (Phoenix International Life Sciences, Montreal, Canada) tubes and centrifuged, and the resulting plasma was placed in plastic tubes and frozen at minimum -10°C until analyzed. Sample Collection for Pharmacodynamic Analysis: Nasal washes for viral cultures were collected twice daily (q12h, morning and evening) on Study Days 1-3, and once daily (q24h, morning) on Study Days 4-7. The morning nasal washes for viral culture were collected prior to the doses of study drug on Study Days 1-7. Susceptibility (IC 50 ) to RWJ-270201 (BCX-1812) was determined for all viral isolates. Analytical Procedures: Plasma samples were analyzed for concentrations of RWJ-270201 (BCX-1812) by a validated LC/MS/MS method. The calibration range of the method was 0.10 ng/mL to 100 ng/mL. The assay was specific and linear over the concentration range of 0.10 ng/mL (lower limit of quantification) and 1000 ng/mL with the calibration curve regression coefficients of determination (r 2 ) being greater than 0.989. 
DATA ANALYSIS AND MODELING
Exploratory Analysis
RWJ-270201 (BCX-1812) pharmacokinetic parameters were determined from the plasma concentration-time profiles using noncompartmental methods. The parameters included maximum concentration (C max , trough concentration (C min ), and area under the plasma concentration-time curve from time 0 hours to 24 hours postdose (AUC 0-24 , calculated by the use of the linear trapezoidal method. For the 200 mg-q12h regimen, AUC 0-12 was estimated. In the case of pharmacodynamic end point, area under the viral titer-time curve (AUC Days 1-7) was determined. This pharamcodynamic end point was estimated as the area under the curve (AUC) from time of first treatment up to and including 7 days after the first dose (ie, Days 1-7). A preliminary analysis was performed to characterize the relationship between pharmacokinetic and pharmacodynamic parameters from the data obtained from these two trials (5) . Figure 1 represents a scatter plot of the AUC of log viral titer versus the area under plasma concentration time curve (AUC 0-24 or AUC 0-12 ) for individual subjects from different doses. There appears to be a graded exposure-response relationship suggesting that higher drug exposure, based on plasma AUC, is associated with greater decrease in viral titer. Based on the preliminary investigation, a modeling strategy was undertaken to describe a population PK/PD relationship between dose, plasma concentrations, and mean viral titer, which is in turn the pharmacological effect for RWJ-270201 (BCX-1812). The following steps were performed in developing the PK/PD model:
Model: A structured approach to population pharmacokinetic modeling was used. RWJ-270201 (BCX-1812) plasma concentration data were analyzed by a nonlinear mixed effects model using the computer program WinNonMix Professional version 2.0.1 (Pharsight Corp, Mountain View, CA) (6). The program was run on a Dell Dimension PC V350 equipped with an Intel Pentium II 350 MHz microprocessor. Tabulation, graphics, and statistical analysis were performed using S-plus (Insightful Corporation, Seattle, WA). The model building process involved establishment of a base pharmacokinetic compartment model, selected by graphical representation of the concentration-time data and information from historical pharmacokinetic experience (7) . This model included no covariates. Subsequent WinNonMix runs were executed separately for each potential covariate in order to evaluate the effect of inclusion of the covariate on a pharmacokinetic parameter. Following these univariate analyses, fixed effects (eg, measurable covariates such as age and weight) that were considered potentially significant were combined in a multivariate analysis. The mixed effect PK parameters are as follows:
In which k a is the first order rate constant of absorption, CL/F is the apparent total body clearance, V 1 /F is the apparent volume of distribution of the central compartment, CL 2 /F is the intercompartmental flow rate divided by the oral bioavailability, V 2 /F is the volume of distribution of the peripheral compartment divided by the oral bioavailability. T I and ? I are fixed-effect and random-effect parameters estimated by WinNonMix. Interindividual variabilities in the pharmacokinetic parameters were modeled with use of exponential error models, respectively, as follows:
In which Y is the population mean parameter and ?Yj represents the difference between the population mean and the value for the jth individual (Yj). The ?'s are zero mean random variables with variance w2. The intraindividual variabilities, or residual errors, in the pharmacokinetic and pharmacodynamic measurements were modeled with the proportional and additive error models, respectively, according to the following: Coij = Cpij • (1+ eij); Coij = Cpij + eij, where Coij and Cpij are the observed and model-predicted concentrations, and eij denotes the residual intrapatient random error, distributed with zero mean and variance s2. To avoid overparameterization, the values of ka, V 2 /F, and CL2/F were fixed to values determined from historical data. Bayesian estimates of individual pharmacokinetic parameter values, such as CLj and Vj , for individual subjects obtained from the WinNonMix model, were used to calculate the cumulative drug AUC for each subject at each time point that the viral titer was measured.
• Population Pharmacodynamic Model: The second step in the modeling strategy was to take the information from the compartmental pharmacokinetic model and develop a pharmacodynamic model that would take the AUC of the plasma drug concentrationtime profile to serve as an input function for the pharmacodynamic model. In order to perform this step, a user-defined model was created using WinNonMix that incorporates an empirical equation describing the antiviral effect of RWJ-270201 (BCX-1812). The pharmacodyamic model consisted of 2 components, VF and DF. VF is a general density function, which can express the viral growth in the absence of the drug. DF is a sigmoidal Emax function, which related the drug exposure to changes in viral titers. The viral titer, F (log transformed) can be described as follows: 
(2) F = log(VF) + log(DF)
In which SCLR is the scaling factor in the viral growth curve VF; T50 is the time to reach 50% of the maximum viral titer; G1 is a sigmoid factor in the viral growth curve VF; and t is the elapsed time from dosing at which viral titer was measured. A time shift of 24 hours was incorporated to account for the start of viral growth at 24 hours prior to drug dosing. DA50 is the drug exposure, or cumulative drug AUC that produces 50% of the maximum drug effect. DAUC is the drug exposure, or cumulative drug AUC calculated by WinNonMix model (Bayesian estimates) for each subject at each time point at which viral titer was measured, and G2 is a sigmoidicity factor in the drug effect curve, DF. I is an index assigned to 0 for viral type A and 1 for viral type B.
The purpose of using separate equations, 1 and 2, was to model the viral growth and the effect of the drug on viral growth independent of each other. By doing so, we were able to assess the time course of viral titers both in the absence of drug (placebo) and during the treatment with RWJ-270201 (BCX-1812). Equation 1 describes the growth of the virus as a function of T50 and shape factor G1, suggesting a nonlinear growth of the influenza viruses. The drug effect factor in equation 2 is a function of drug exposure and shape factor G2. The resultant equation 3, which is the product of equations 1 and 2, describes the viral titer over time for both active drug and placebo. For a placebo subject, AUC will go to zero in equation 2 and DF will approach unity. Hence the log viral titers, F, which were measured in the placebo subject, will be a function of simply VF. On the other hand, for a subject receiving active drug, the log viral titers, F, will be a function of both VF and DF.
PD Model Building: The effect of viral type on fixed-effect PD parameters, q1, q2, q3, q4, and q5 were tested in step-wise model building. The effect of viral type was defined as fractional changes in PD parameters of viral type B with respect to that of viral type A. The optimal pharmacodynamic model was chosen based on goodness of fit criteria including diagnostic scatter plots, decreases in interpatient variances, and the value of the objective function. Models were built in step-wise manner with incremental covariate factors. The objective function was used for hypothesis testing to discriminate among hierarchical models. In the expanded model, a certain parameter representing a covariate would be estimated, whereas in the reduced model it would be fixed to zero allowing the expanded model to collapse to its reduced counterpart. The difference in values of the WinNonMix objective function between these 2 related models was calculated. Such a parameter would only be retained in the model to represent the significant influence of a certain covariate if the difference in the objective function value was ³ 8, as recommended in the guidance for population pharmacokinetics issued by the FDA (8) . The base model is the one in which all parameters except q1, q2, q3, q4, and q5 were fixed to zero. Initially, each null hypothesis tested only 1 covariate against the base model by allowing the parameters associated with the covariate to be estimated. The covariates with decrease in OF < 4 are discarded, and the remaining covariates were ranked according to their drop in OF. The model with the largest drop in OF was then used as the new reference model to include other covariates one by one starting with the strongest influence according to the rank order established previously. The covariates with decrease in OF > 8 were regained in the model, and the covariates with decrease in OF < 8 were omitted. The first-order method was used in the model-building procedure. This method was found to be computationally too intensive to use first order conditional estimation (FOCE) method in WinNonmix for each model building step. The criteria for acceptance of WinNonMix estimation included the following: (1) convergence of the objective function (ie, a "successful termination" statement from the WinNonMix program), (2) standard error of the estimates < 30% of the estimate itself, and (3) termination of the covariance step without warnings.
RESULTS
Population Pharmacokinetic Analysis
A mixed-effect 2-compartmental open model with firstorder absorption and elimination were best fitted to the pharmacokinetic data. Figure 2 shows the plot of the observed versus the predicted concentrations, showing that both the predicted and the observed concentrations fall along the line of identity. The population pharmacokinetic parameter estimates (95% confidence intervals of the estimates associated with the base model) along with their intersubject variability and the residual variability in the pharmacokinetic parameters are provided in Table 2 . As shown in the table, the population pharmacokinetic parameter estimates are well characterized. As a measure of precision of the WinNonMix parameter estimate, the coefficient of variation of CL/F was 7.6% and that of V1/F was 5.5%, respectively. The interindividual variability of CL/F, V1/F and ka were 30.6%, 39.6%, and 42.4%, respectively. The residual variability was 11.1%. Mean Bayesian pharmacokinetic parameter estimates across all dose groups for both influenza A and B virus study is provided in Table 3 . Estimates of ka, V1/F, and CL/F were similar among the dose cohorts (data not shown). CL/F estimates appeared to be similar across dose groups. From the Bayesian approach, CL estimates were quite similar (301 L/h-296 L/h, data not shown) to values seen in previous Phase I studies. In the case of volume distribution, the Bayesian estimates provided higher Volume distribution values (874 L-960 L), and is regarded as less variable. A step-wise model building was performed on the effect of the covariates on the pharmacokinetic parameters 9 :
the results are provided in Table 4 . From Table 4 , weight was the most significant covariate for all estimated pharmacokinetic parameters. Genderrelated differences were also found with higher clearance values for male subjects; however, the gender effect became nonsignificant when weight was included in the model. Age and height were not found to be correlated with the clearance. Therefore, only the weight effect was kept in the final pharmacokinetic model to be linked to pharmacodynamic effect.
Population Pharmacodynamic Analysis
The Pharmacokinetic/Pharmacodynamic model integrated the pharmacokinetic and the pharmacodynamic data through equations (1) to (3). The estimates of the log viral titer F, which was generated from the model, were found to best describe the data for active drug and placebo. Graphical results for the modelfit relationships with RWJ-270201 (BCX-1812) log-viral titers are presented in Figures 3A and 3B . In Figure 3A , plots C and D show 2-log folds drop in the viral titers at 48 hours as compared with the placebo. The intensity of the drop in the viral titers for active drug is more pronounced compared with the placebo. Similarly, results were seen in influenza B virus for both the loading dose and standard dosage regimen ( Figure 3B ). In both studies, there was a good fit of the PK/PD model predicted viral titers to the observed viral titers.
The results of this model building show that viral type A and B are significant covariates of T50 and DA50. The population pharmacodynamic parameter estimates obtained from the WinNonMix are provided in Table 6 . The step-wise model building for the pharmacodynamic data was performed to understand if there is any influence of the viral types A and B on the viral growth and drug exposure. The model building was similar to that for the pharmacokinetic model, in which fixed effects such as T50 and DA50 were evaluated for any potential significant effect on the viral types A and B. Backward elimination of 1 fixed effect covariate at a time (each time replacing the other covariates) was then performed to select the model. Of the covariate models examined, those that showed a significant effect from the base viral titer were included in the final pharmacodynamic model. Table 5 provides the WinNonMix model building results. In terms of the precision of the WinNonMIX estimates, the estimated interindividual coefficient of variation for T50, DA50, SCLR, G1, and G2 were 8.2%, 10.6%, 10.2%, 10.2%, and 17.8%, respectively. The residual error was 14%. The Bayesian estimates of the individual PD parameters obtained from the WinNonMix model are provided in Table 7 . The table shows that the estimates for DA50 were 74% higher for influenza B virus as compared with influenza A virus. There was also a 20% increase in the T50 values for B virus as compared with A virus. The percent deviations of the Bayesian estimates for T50 and DA50 were relatively smaller for influenza A compared with influenza B virus.
DISCUSSION
This report describes the analysis of pharmacokinetic and pharmacodynamic data obtained from challenge studies conducted in healthy subjects during the development of RWJ-270201 (BCX-1812) for the treatment of influenza A and B virus. The population pharmacokinetic/pharmacodynamic analysis consisted of 2 steps: population pharmacokinetic model building followed by population pharmacodynamic model building.
The results of the population approach with a 2-compartmental model reasonably fitted the plasmaconcentration time data. The analysis was unable to detect any pharmacokinetic differences associated with either age or gender. The power to detect effects due to these factors may have been limited by the relatively small number of subjects in the age group of 18 to 45 years. In the present study, from the Bayesian estimates, clearance values were not influenced by viral type. There was a reasonable agreement in the oral clearance values obtained in subjects inoculated with influenza viruses (301 L/h) and in healthy subjects (296 L/h, data not shown) in the previous studies. These suggest that the disposition and elimination process of RWJ-270201 (BCX-1812) is not affected by the presence of influenza A and B virus. However, for the volume of distribution, estimates obtained from this study were different than estimates observed in the study of healthy subjects 874 L to 960 L). The reasons for the difference in estimates of the volume of distribution between these studies are not clear but may be due to the sparse sampling used in the challenge study and the inability to estimate the interindividual variability for volume distribution V1/F.
Another important result of this paper was the population analysis of the pharmacodynamic data for both influenza A and B virus. A PK/PD model was successfully developed to relate the drug exposure to the course of the change in viral titer. Based on the mixed effect pharmacodynamic analysis, there was a good fit of the PD model to the observed log viral titer data for both placebo-and active -treated subjects. Recent reports examined quantitatively the effect of antiretroviral agents to human immunodeficiency virus (HIV)-infected patients. Models that were developed to describe the PK/PD of antiretroviral agents were based on the CD+4 cell counts and HIV-1 RNA levels from the baseline in HIV -positive patients. 10, 11, 12 As this is a life-threatening disease, the studies set up to evaluate the clinically effective dose of antiretroviral agents are conducted on HIV -positive patients. However, in the case of influenza, the safest way to evaluate the effect of antiviral agents is to inoculate healthy subjects with experimental influenza A and B virus and compare it with the placebo. As the influenza is a self-limiting disease, it is most likely that both the active drug and the placebo will follow a similar pattern with respect to decline in the viral titers over a period of time. Unlike the antiretroviral agents, the pharmacodynamic assessment in this case is based on the differences in the log area under the viral titer between active drug and the placebo subjects. Therefore, there is a much greater need to model both the placebo and the active drug simultaneously.
The Figures 3A and 3B represent the time course of mean log viral titers for both influenza A and B virus. As seen in Figure 3A , there appears to be a good fit of the PK/PD model predicted viral titers for both the placebo and the active drug treatments. What is quite interesting in this figure is that the intensity of drop in the viral titers appears to be profound in Plots C and D (200 mg bid and 400 mg qd regimen) as compared with Plots A and B (100 mg qd and 200 mg qd regimen). This difference also suggests that a larger drug exposure is needed to have a significant decrease in the viral titers as compared with the placebo. Another interesting observation in the comparison of the viral titers between the loading dose and the standard dose regimen for influenza B virus is shown in Figure 3B . In plots E and F, the time to reach the maximum effect as well as the intensity of drop in the viral titer appears to be similar for both the loading and the standard dose regimens. However, as the maintenance dose (loading dose regimen) starts acting on the body, the changes in the viral titers follow a pattern similar fashion to the placebo. On the other hand, in the standard dose regimen (800 mg qd on Days 1-5) there is a sustained effect of the drop in the viral titers for the standard regimen as compared with the placebo. This reemphasizes our notion that larger drug exposure is associated with the decrease in the viral titers.
From the mixed effect PD analysis there appears to be a significant effect of the PD parameters, T50 and DA50, on the viral types A and B. Based on the Bayesian estimates, it appears that the DA50, which is the drug AUC needed to achieve 50% of the maximum drug effect, is higher for the B virus than for the A virus (1989 ng*h/mL vs 1089 ng*h/mL). In addition, the time taken to reach 50% of the maximum viral AUC was longer in the case of B virus than in the case of A virus (67.5 hours and 45.7 hours, respectively). In order to understand the differences in PD parameters between these 2 viruses, a histogram was plotted to understand the distribution of the viral growth between A and B. Data shown in Figure  4 suggest that the time taken for the virus to grow and die is quicker in A than in B. Influenza B appears to stay in the body longer compared with influenza A. This data also suggest that virus B may be more potent than virus A. Based on this PK/PD model, Bayesian estimates appear to forecast the need to have a larger exposure of drug in order to widen coverage of influenza challenge strains in addition to A and B virus. Therefore, the selection of a loading dose or a standard regimen appears to be a judicious decision for improved efficacy and decreased emergence of viral resistance in a regular outbreak of influenza. In conclusion, a successful pharmacokineticpharmacodynamic model was used to characterize the effect of RWJ-270201 (BCX-1812) on the influenza A and B virus. The results from this study have shown that RWJ-270201 (BCX-1812) as a neuraminidase inhibitor provides a potent and durable suppression of influenza A and B virus.
